Recent Evidence Regarding a Role for Cdk5 Dysregulation in Alzheimer's Disease

E-ISSN： 1875-5828|1|1|33-38

ISSN： 1567-2050

Source： Current Alzheimer Research, Vol.1, Iss.1, 2004-01, pp. : 33-38

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Addressing the complex etiology of Alzheimer’’s disease: the role of p25/Cdk5

By Mungenast Alison E Tsai Li-Huei

Future Neurology, Vol. 6, Iss. 4, 2011-07 ,pp. : 481-496

Future Medicine

Access to resources Recommend Favorite

Cdk5 as a Drug Target for the Treatment of Alzheimer’s Disease

By Lau Lit-Fui Seymour Patricia A. Sanner Mark A. Schachter Joel B.

Journal of Molecular Neuroscience, Vol. 19, Iss. 3, 2002-12 ,pp. : 267-274

Humana Press, Inc

Access to resources Recommend Favorite

CDK5 and MAPT Gene Expression in Alzheimer's Disease Brain Samples

Current Alzheimer Research, Vol. 15, Iss. 2, 2018-01 ,pp. : 182-186

Bentham Science Publishers

Access to resources Recommend Favorite

Alzheimer's Disease and Environmental Exposure to Lead: The Epidemiologic Evidence and Potential Role of Epigenetics

Current Alzheimer Research, Vol. 9, Iss. 5, 2012-06 ,pp. : 563-573

Bentham Science Publishers

Access to resources Recommend Favorite

The NGF Metabolic Pathway in the CNS and its Dysregulation in Down Syndrome and Alzheimer’s Disease

Current Alzheimer Research, Vol. 13, Iss. 1, 2016-01 ,pp. : 53-67

Bentham Science Publishers

Access to resources Recommend Favorite